ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2011 | $680,000 | Replaced |
| 2nd Quarter - Amendment | Aug 31, 2011 | $680,000 | Replaced |
| 2nd Quarter - Amendment | Aug 20, 2013 | $680,000 | Yes |
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 5 (Help Efficient, Accessible, Low-cost Timely Healthcare Act of 2011) - issues related medical malpractice reform HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to development of antibiotics
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| KIRSTEN POWELL New | — |
| BRADLEY ALLEN ROSSIN | — |
| HEATHER STRAWN | — |
Taxation/Internal Revenue Code TAX
Issues related to reform of tax code and possible timing of any such reform bill (no bill number yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW KAPLAN | — |
| DANNY LY | — |
Trade (domestic/foreign) TRD
Trade Agreements Act and country or origin issues in government contracting (no bill number yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW KAPLAN | — |
| HEATHER STRAWN | — |
Copyright/Patent/Trademark CPT
S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issues HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issuess related to the development of antibiotics Participate in executive branch discussions regarding intellectual property issues arising in foreign countries Discussions regarding global/free trade agreements and protection of intellectual property
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| BRADLEY ALLEN ROSSIN | — |
| HEATHER STRAWN | — |
Medicare/Medicaid MMM
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization S. 1251 - issues related to Medicare fraud and abuse laws HR 2190, S. 1206 - issues related to Medicare Part D rebates HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152), HR 2248 - issues related to health care reform legislation and implementation, including proposed changes to the Medicare Program regarding pharmaceutical rebates and price negotiation
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| BRADLEY ALLEN ROSSIN | — |
| BELA SASTRY New | Office of Asst. Sec'y Planning & Evaluation |
| HEATHER STRAWN | — |
Consumer Issues/Safety/Products CSP
Legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer (anti-counterfeiting/anti-diversion efforts) HR 2245, S. 296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages S. 319 and related legislative proposals regarding prescriptiond drug importation and safety issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| HEATHER STRAWN | — |
Government Issues GOV
Monitoring developments regarding the Foreign Corrupt Practices Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| HEATHER STRAWN | — |
Pharmacy PHA
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) V (no bill number yet) HR 2112, HR 2190, S1206 - Proposed legisalation regarding FDA appropriations
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| BRADLEY ALLEN ROSSIN | — |
| HEATHER STRAWN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.